Parvinder Hothi
Overview
Explore the profile of Parvinder Hothi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
750
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S, et al.
Sci Adv
. 2024 Jun;
10(23):eadj7706.
PMID: 38848360
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity and treatment-induced shifts in phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This...
2.
Turkarslan S, He Y, Hothi P, Murie C, Nicolas A, Kannan K, et al.
medRxiv
. 2024 Apr;
PMID: 38633778
Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, and its treatment remains challenging in part due to extensive interpatient...
3.
Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S, et al.
bioRxiv
. 2024 Feb;
PMID: 38370784
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity and treatment-induced shifts in phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This...
4.
Hothi P, Cobbs C
J Clin Invest
. 2023 Jul;
133(13).
PMID: 37395278
The most active human endogenous retrovirus K (HERV-K) subtype, HML-2, has been implicated as a driver of oncogenesis in several cancers. However, the presence and function of HML-2 in malignant...
5.
Bustos M, Rahimzadeh N, Ryu S, Gross R, Tran L, Renteria-Lopez V, et al.
Lab Invest
. 2022 Jan;
102(7):711-721.
PMID: 35013528
Glioblastoma (GBM) is still one of the most commonly diagnosed advanced stage primary brain tumors. Current treatments for patients with primary GBM (pGBM) are often not effective and a significant...
6.
Park J, de Lomana A, Marzese D, Juarez T, Feroze A, Hothi P, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34202449
Brain tumors are among the most lethal tumors. Glioblastoma, the most frequent primary brain tumor in adults, has a median survival time of approximately 15 months after diagnosis or a...
7.
Orozco J, Knijnenburg T, Manughian-Peter A, Salomon M, Barkhoudarian G, Jalas J, et al.
Nat Commun
. 2018 Nov;
9(1):4627.
PMID: 30401823
Optimal treatment of brain metastases is often hindered by limitations in diagnostic capabilities. To meet this challenge, here we profile DNA methylomes of the three most frequent types of brain...
8.
Salomon M, Orozco J, Wilmott J, Hothi P, Manughian-Peter A, Cobbs C, et al.
Sci Data
. 2018 Nov;
5:180245.
PMID: 30398472
Brain metastases (BM) are one the most lethal and poorly managed clinical complications in cancer patients. These secondary tumors represent the most common intracranial neoplasm in adults, most frequently originating...
9.
Diaz P, Horne E, Xu C, Hamel E, Wagenbach M, Petrov R, et al.
Eur J Med Chem
. 2018 Oct;
159:74-89.
PMID: 30268825
Small molecules that target microtubules (MTs) represent promising therapeutics to treat certain types of cancer, including glioblastoma multiform (GBM). We synthesized modified carbazoles and evaluated their antitumor activity in GBM...
10.
Puchalski R, Shah N, Miller J, Dalley R, Nomura S, Yoon J, et al.
Science
. 2018 May;
360(6389):660-663.
PMID: 29748285
Glioblastoma is an aggressive brain tumor that carries a poor prognosis. The tumor's molecular and cellular landscapes are complex, and their relationships to histologic features routinely used for diagnosis are...